Your browser doesn't support javascript.
loading
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers.
Anderhub, Simon J; Mak, Grace Wing-Yan; Gurden, Mark D; Faisal, Amir; Drosopoulos, Konstantinos; Walsh, Katie; Woodward, Hannah L; Innocenti, Paolo; Westwood, Isaac M; Naud, Sébastien; Hayes, Angela; Theofani, Efthymia; Filosto, Simone; Saville, Harry; Burke, Rosemary; van Montfort, Rob L M; Raynaud, Florence I; Blagg, Julian; Hoelder, Swen; Eccles, Suzanne A; Linardopoulos, Spiros.
Afiliação
  • Anderhub SJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Mak GW; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Gurden MD; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Faisal A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Drosopoulos K; The Breast Cancer Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Walsh K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Woodward HL; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Innocenti P; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Westwood IM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Naud S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Theofani E; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Filosto S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Saville H; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Burke R; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • van Montfort RLM; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Blagg J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Hoelder S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
  • Linardopoulos S; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. spiros.linardopoulos@icr.ac.uk.
Mol Cancer Ther ; 18(10): 1696-1707, 2019 10.
Article em En | MEDLINE | ID: mdl-31575759
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Triazóis / Pontos de Checagem do Ciclo Celular / Neoplasias de Mama Triplo Negativas / Fuso Acromático Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Triazóis / Pontos de Checagem do Ciclo Celular / Neoplasias de Mama Triplo Negativas / Fuso Acromático Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido